

***Candida auris* in Germany and Previous Exposure to Foreign Healthcare**

Axel Hamprecht, Amelia E. Barber, Sibylle C. Mellinghoff, Philipp Thelen, Grit Walther, Yanying Yu, Priya Neurgaonkar, Thomas Dandekar, Oliver A. Cornely, Ronny Martin, Oliver Kurzai, on behalf of the German *Candida auris* Study Group¹

Author affiliations: German Centre for Infection Research, Cologne, Germany (A. Hamprecht, S.C. Mellinghoff, O.A. Cornely); University of Cologne, Cologne (A. Hamprecht, O.A. Cornely); Leibniz Institute for Natural Product Research and Infection Biology–Hans-Knoell-Institute, Jena, Germany (A.E. Barber, G. Walther, O. Kurzai); University Hospital Cologne, Cologne (S.C. Mellinghoff, P. Thelen); University of Würzburg, Würzburg, Germany (Y. Yu, P. Neurgaonkar, T. Dandekar, R. Martin, O. Kurzai)

DOI: <https://doi.org/10.3201/eid2509.190262>

The emerging yeast *Candida auris* has disseminated worldwide. We report on 7 cases identified in Germany during 2015–2017. In 6 of these cases, *C. auris* was isolated from patients previously hospitalized abroad. Whole-genome sequencing and epidemiologic analyses revealed that all patients in Germany were infected with different strains.

Candida auris is an emerging yeast that was initially described in 2009 after a case of otitis externa in Japan (1). Since then, healthcare-associated infections have been reported worldwide (2). *C. auris* has caused outbreaks in hospitals in Asia, Africa, and Latin America (2–4). In Europe, 620 *C. auris* cases were observed during 2013–2017 (24% infections, 76% colonizations), including 7 cases in Germany (5). Most *C. auris* isolates exhibit resistance to fluconazole, and susceptibility to other azoles, amphotericin B, and echinocandins varies among isolates. Some strains show resistance to all 3 classes of antifungal drugs (6).

We report on the occurrence of *C. auris* in Germany and its link to prior healthcare exposure in the Middle East, Asia, Africa, or the United States. *C. auris* was isolated from 7 patients (4 male, 3 female, all in different, unrelated hospitals) during November 2015–December 2017 (Appendix Table, <http://wwwnc.cdc.gov/EID/article/25/9/19-0262-App1.pdf>). Six of the patients had previously been treated in healthcare centers outside Germany and were transferred to Germany for further treatment. No further suspicious cases or isolates were reported to the National

Reference Centre for Fungal Infections (Jena, Germany); however, reporting is not mandatory, and the possibility of missed cases cannot be excluded.

Of the 7 patients, 3 had been in isolation before detection of *C. auris* as a result of known colonization with carbapenemase-producing *Enterobacteriaceae*. No secondary *C. auris* cases were detected in any of the hospitals until March 2019. However, because no contact screening was performed, transmission resulting in asymptomatic carriage cannot be excluded.

Isolates from 6 patients were available for further testing. Biochemical identification of isolates by API ID 32C resulted in misidentification as *C. sake* (5 of 6) or *C. intermedia* (1 of 6). In contrast to previous versions, Vitek 2 version 08.01 (bioMérieux, <https://www.biomerieux-diagnostics.com>) identified all isolates as *C. auris* with 93%–99% likelihood. With VitekMS (bioMérieux) matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, no identification was achieved. However, a recent database update for VitekMS (version 3.2), which was not available at the time of our testing, corrected the identification failure in the VitekMS (data not shown). The Bruker Biotyper system (<https://www.bruker.com>) correctly identified all strains, albeit some with a low score (1.6–1.99). Whereas Bruker recommends that a score of 2.0 be used for species identification, a score >1.7 has been shown to be sufficient for reliable species identification (7). At the time of testing, Bruker's research-use-only library did not include a *C. auris* strain of the South Asian clade, which most of the German isolates belong to. Because *C. auris* exhibits considerable heterogeneity of mass spectra between geographic clusters, this missing clade likely explains the low scores (8).

Molecular identification using internal transcribed spacer technology identified all *C. auris* strains with 100% identity to the reference strain DSM 21092/CBS 10913. For available isolates, we performed whole-genome sequencing and aligned reads to the B8441 v2 reference genome (Figure; Appendix). A phylogenetic tree generated from whole-genome single-nucleotide polymorphism (SNP) data indicated that the isolates NRZ-2015-214, NRZ-2017-288, NRZ-2017-367, NRZ-2017-394/1-2, and NRZ-2017-505 belong to the South Asian clade, whereas NRZ-2018-545 was related to the African clade (Figure). In line with previous studies, the genetic differences observed between isolates of the same clade were small (30–800 SNPs), whereas differences between clades were large (36,000–147,000 SNPs) (4,9). Whole-genome data show that all cases identified in Germany harbor unique isolates, thus excluding transmission between these patients (Figure). As a control, the clonality of serial isolates NRZ-2017-394/1 and NRZ-2017-394/2, taken from the same patient on 2 different occasions, was confirmed; the 2 isolates were separated by only a single SNP (Figure).

¹Group members are listed at end of this article.




Figure. Genetic relationships of *Candida auris* isolates based on whole-genome sequencing SNP analysis. A) Maximum-likelihood phylogeny of *C. auris* isolates from Germany (indicated by NRZ prefix) inferred to reveal a possible geographic origin. The isolates were contrasted against strains representing the 4 different clades of *C. auris*: South American (strain B11243 from Venezuela), East Asian (B11220 from Japan), South African (B11221 from South Africa), and South Asian (B8441 from Pakistan and 6684 from India). B) Higher resolution of the tree shown in panel A to better visualize the relationship between the isolates belonging to the South Asian clade. Scale bars in panels A and B indicate nucleotide substitutions per site. C) SNP counts between the genomes of the isolates from Germany and the representative strains from the different clades. SNP, single-nucleotide polymorphism.

MICs of fluconazole were high for all isolates (>64 mg/L), whereas the MICs for other antifungals were variable (Appendix Table). With the exception of NRZ-2017-545, all isolates carried either the Y132F or the K143R mutations in the *ERG11* gene. However, although these mutations are linked to azole resistance, they did not result in elevated MICs for all azoles in these isolates (Appendix Table) (10). We identified a S639Y mutation in the *FKS1* hotspot 1 of isolate NRZ-2017-505, which was highly resistant to anidulafungin (MIC 16 mg/L).

In conclusion, *C. auris* has so far been isolated from individual cases in Germany. Most of these cases (6 of 7) occurred in patients who had previously been hospitalized abroad and were admitted to hospitals in Germany for continuation of medical treatment. No information on contact or environmental screening was

available; such screening was likely not performed in most institutions. Thus, silent transmission and resulting carriage may have occurred unnoticed. However, no secondary cases were detected in any of the 7 hospitals affected.

Members of the German *Candida auris* Study Group: Gerhard Haase (Labordiagnostisches Zentrum, Universitätsklinikum RWTH Aachen, Aachen, Germany); Jette Jung (Max von Pettenkofer-Institut, Munich, Germany); Heike Freidank (Städtisches Klinikum München GmbH, Munich); Michaela Simon (Institut für Med. Mikrobiologie und Hygiene, Regensburg, Germany); Jörg Steinmann (Institut für Klinikhygiene, Medizinische Mikrobiologie und Klinische Infektiologie, Universitätsinstitut der Paracelsus Medizinischen Privatuniversität, Nuremberg, Germany).

Acknowledgments

We thank Shneh Sethi for helpful advice and Sabrina Mündlein, Grit Mrotzek, and Ahmad Saleh for excellent technical assistance.

The German National Reference Center NRZMyk is funded by the Robert Koch Institute from funds provided by the German Ministry of Health (grant no. 1369-240). Calculations were performed on the Freiburg Galaxy server using computing services provided by the Center of Genetic Epidemiology (Danish Technical University, Lyngby, Denmark). The Freiburg Galaxy project is supported by the Collaborative Research Centre 992 Medical Epigenetics (DFG grant no. SFB 992/1 2012) and German Federal Ministry of Education and Research (BMBF grant no. 031 A538A). T.D. acknowledges support by the Deutsche Forschungsgemeinschaft (project no. 210879364–TRR 124/B1).

About the Author

Dr. Hamprecht is a clinical microbiologist at the Institute for Medical Microbiology, Immunology and Hygiene and professor for antibiotic resistance of gram-negative pathogens at the University of Cologne, Germany, and the German Centre for Infection Research (DZIF), also in Cologne. His research interests include multidrug-resistant organisms (mainly Enterobacterales and fungi), their resistance mechanisms, and the improvement of diagnostic methods.

References

1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol Immunol*. 2009;53:41–4. <http://dx.doi.org/10.1111/j.1348-0421.2008.00083.x>
2. Chowdhary A, Voss A, Meis JF. Multidrug-resistant *Candida auris*: “new kid on the block” in hospital-associated infections? *J Hosp Infect*. 2016;94:209–12. <http://dx.doi.org/10.1016/j.jhin.2016.08.004>
3. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First hospital outbreak of the globally emerging *Candida auris* in a European hospital. *Antimicrob Resist Infect Control*. 2016;5:35. <http://dx.doi.org/10.1186/s13756-016-0132-5>
4. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant *Candida auris* on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. *Clin Infect Dis*. 2017;64:134–40. <http://dx.doi.org/10.1093/cid/ciw691>
5. Kohlenberg A, Struelens MJ, Monnet DL, Plachouras D; The *Candida auris* Survey Collaborative Group. *Candida auris*: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. *Euro Surveill*. 2018;23:18-00136. <http://dx.doi.org/10.2807/1560-7917.ES.2018.23.13.18-00136>
6. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A, et al.; *Candida auris* Incident Management Team. *Candida auris*: a review of the literature. *Clin Microbiol Rev*. 2017;31:e00029-17. <http://dx.doi.org/10.1128/CMR.00029-17>
7. Hamprecht A, Christ S, Oestreich T, Plum G, Kempf VA, Götting S. Performance of two MALDI-TOF MS systems for the identification of yeasts isolated from bloodstream infections and cerebrospinal fluids using a time-saving direct transfer protocol. *Med Microbiol Immunol (Berl)*. 2014;203:93–9. <http://dx.doi.org/10.1007/s00430-013-0319-9>
8. Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F, et al. Evidence of genotypic diversity among *Candida auris* isolates by multilocus sequence typing, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. *Clin Microbiol Infect*. 2016;22:277e1–9. <http://dx.doi.org/10.1016/j.cmi.2015.10.022>
9. Magobo RE, Corcoran C, Seetharam S, Govender NP. *Candida auris*-associated candidemia, South Africa. *Emerg Infect Dis*. 2014;20:1250–1. <http://dx.doi.org/10.3201/eid2007.131765>
10. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, et al. A multicentre study of antifungal susceptibility patterns among 350 *Candida auris* isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. *J Antimicrob Chemother*. 2018;73:891–9. <http://dx.doi.org/10.1093/jac/dkx480>

Address for correspondence: Oliver Kurzai, University of Würzburg Institute for Hygiene and Microbiology, Josef-Schneider-Straße 2 / E1, Würzburg 97080, Germany; email: okurzai@hygiene.uni-wuerzburg.de

Characterization of Clinical Isolates of *Talaromyces marneffe* and Related Species, California, USA

Linlin Li, Katelyn Chen, Nirmala Dhungana, Yvonne Jang, Vishnu Chaturvedi,¹ Ed Desmond²

Author affiliation: California Department of Public Health, Richmond, California, USA

DOI: <https://doi.org/10.3201/eid2509.190380>

Talaromyces marneffe and other *Talaromyces* species can cause opportunistic invasive fungal infections. We characterized clinical *Talaromyces* isolates from patients in California, USA, a non-*Talaromyces*-endemic area, by a multiphasic approach, including multigene phylogeny, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and phenotypic methods. We identified 10 potentially pathogenic *Talaromyces* isolates, 2 *T. marneffe*.

¹Current affiliation: New York State Department of Health, Albany, New York, USA.

²Current affiliation: Hawaii State Department of Health, Pearl City, Hawaii, USA.

Candida auris in Germany and Previous Exposure to Foreign Healthcare

Appendix

Materials and Methods

Isolates

Since the worldwide emergence of *Candida auris*, the National Reference Centre for Fungal Infections (NRZMyk) has issued several alerts on this species and informed diagnostic laboratories in Germany to send all suspicious *Candida* spp. isolates to the reference laboratory for identification. In total, during November 2015–December 2017, we collected 8 isolates from 6 patients; for 1 case (reliable identification with Bruker MALDI), no isolate was available.

Identification and Susceptibility Testing

We identified all isolates by biochemical methods (Vitek2 Yeast Card, API ID32C V4.0 (bioMérieux) and by MALDI-TOF using 2 different systems (VitekMS, bioMérieux or Biotyper Microflex, Bruker Daltonics) and 2 protein extraction protocols, as previously described (1). In addition, we identified all isolates by PCR and sequencing of the internal transcribed spacer (ITS) (2).

The isolates were tested by broth microdilution according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards and minimal inhibitory concentrations (MIC) for fluconazole, itraconazole, posaconazole, voriconazole, anidulafungin, and amphotericin B were determined (EUCAST E.DEF 7.3.1. 2017, www.eucast.org).

DNA Isolation

We isolated fungal DNA with a phenol-free procedure, as described previously (3). We analyzed the quality of the isolated DNA by Nanodrop and with an Invitrogen Qubit Fluorometer (<https://www.thermofisher.com>).

Whole-Genome Sequencing

Library preparation and whole-genome sequencing of *C. auris* isolates was performed by either GATC (Konstanz, Germany) or LGC Genomics (Berlin, Germany) on the Illumina platform using 2x 150-bp paired end reads. Illumina adapters were removed from the GATC-sequenced isolates using Trim Galore version 0.4.3.1 (Babraham Institute, <https://www.babraham.ac.uk>). Further data processing was performed using the CSI Phylogeny Pipeline (4). Briefly, reads were mapped to the B8441 v2 reference genome using BWA version 0.7.12 (5). SNP calling was performed using SAMtools version 0.1.18 (6). Following variant detection, SNPs were filtered for a minimum depth of 10, minimum relative depth of 10, minimum SNP quality of 30, and a Z-score of greater than 1.96. No SNP pruning (removal of closely spaced SNPs) was performed to better separate closely related isolates. SNPs were then concatenated and maximum-likelihood phylogeny inferred using FastTree version 2.1.7 (7). For comparison of the isolates in this study to reference strains from other *C. auris* clades, raw sequence data from the Indian isolate 6684 (BioSample ID SAMN03200169), the Japanese isolate B11220 (BioSample ID SAMN05379608), the South African isolate B11221 (BioSample ID SAMN05379609), and the Venezuelan isolate B11243 (BioSample ID SAMN05379619) were downloaded from the National Center for Biotechnology Information (NCBI) and processed using the same pipeline.

Data Availability

Raw sequence read files were uploaded to the NCBI Sequence Read Archive and are publicly available under BioProject IDs PRJNA485145, PRJNA485239, PRJNA485259, PRJNA485409, PRJNA485414, and PRJNA485415.

Clinical Case Presentations

Patient 1 was admitted for a prosthetic joint infection, which was first diagnosed and treated with antimicrobial drugs in Oman. After hospital admission in Germany and replacement of the prosthesis, a febrile episode occurred and *C. auris* was isolated from blood cultures. The patient recovered after treatment with an echinocandin and *C. auris* has not been isolated in subsequent hospital stays.

Patient 2 was treated in the intensive care unit for systemic inflammatory response syndrome. *C. auris* was detected incidentally when the tip of the central venous catheter was sent to the microbiology department as part of the clinical routine. The patient did not receive any antifungal treatment, as no clinical manifestation of *C. auris* infection was observed; the patient is still alive. This patient had no known history of travel or hospitalization abroad within the past year.

Patient 3 had an intracranial hemorrhage that had previously been treated in a Saudi Arabian healthcare facility. Because of a known colonization with carbapenemase-producing Enterobacteriaceae, the patient was placed in a single room. Culture of the catheter urine revealed growth of 10^5 CFU/mL of *C. auris*. Even though urinary catheters were changed several times, *C. auris* was isolated from 2 follow-up urine specimens. Furthermore, *C. auris* was grown from the groin and the tracheostomy. In the absence of any signs of infection in the later course, the patient was transferred to rehabilitation without further treatment of *C. auris*.

Patient 4 was transferred to Germany from Dubai because of a neurologic disorder. *C. auris* was isolated from catheter urine. No treatment was initiated, as the patient was asymptomatic and was discharged alive.

Patient 5 had a multiple trauma, which was initially treated in Russia. From an intraabdominal sample taken during surgery, *Enterococcus faecalis*, *E. avium*, and *C. auris* were isolated. Treatment with ampicillin–sulbactam and amphotericin B was initiated. The patient was transferred to another hospital in good condition 10 days after surgery.

Patient 6 was treated in Germany for sequelae of an injury originating in Afghanistan. Because of systemic signs of infection, blood cultures were drawn, revealing the presence of *C. auris*. Infection control measures were implemented for this patient after detection of *C. auris*. Because the isolate had elevated MICs for echinocandins, treatment with liposomal amphotericin B and voriconazole was initiated. *C. auris* was also isolated from the urine, likely as a result of an infection of the renal pelvis and the presence of several large kidney stones. Candiduria has not improved for >6 months despite prolonged therapy with voriconazole and amphotericin B. However, since >6 months, no *C. auris* is detectable from this patient's specimen.

Patient 7 was admitted for the treatment of tetraplegia of unknown origin. In the personal history of the patient, previous hospitalizations were recorded in Kenya (2017), Germany (2016),

the United States (2015), and the UK (2014). *C. auris* was grown from the urine but was not treated, as there were no symptoms of a urinary tract infection. The patient was still alive as of November 2018. No further information is available.

References

1. Hamprecht A, Christ S, Oestreicher T, Plum G, Kempf VA, Götting S. Performance of two MALDI-TOF MS systems for the identification of yeasts isolated from bloodstream infections and cerebrospinal fluids using a time-saving direct transfer protocol. *Med Microbiol Immunol (Berl)*. 2014;203:93–9. <http://dx.doi.org/10.1007/s00430-013-0319-9>
2. White TBT, Lee S, Taylor JW. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. *PCR protocols: a guide to methods and applications*. New York: Academic Press; 1990. p. 315–22.
3. Walther G, Pawłowska J, Alastruey-Izquierdo A, Wrzosek M, Rodriguez-Tudela JL, Dolatabadi S, et al. DNA barcoding in Mucorales: an inventory of biodiversity. *Persoonia*. 2013;30:11–47. <http://dx.doi.org/10.3767/003158513X665070>
4. Kaas RS, Leekitcharoenphon P, Aarestrup FM, Lund O. Solving the problem of comparing whole bacterial genomes across different sequencing platforms. *PLoS One*. 2014;9:e104984. <http://dx.doi.org/10.1371/journal.pone.0104984>
5. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009;25:1754–60. <http://dx.doi.org/10.1093/bioinformatics/btp324>
6. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al.; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25:2078–9. <http://dx.doi.org/10.1093/bioinformatics/btp352>
7. Price MN, Dehal PS, Arkin AP. FastTree 2—approximately maximum-likelihood trees for large alignments. *PLoS One*. 2010;5:e9490. <http://dx.doi.org/10.1371/journal.pone.0009490>

Appendix Table. Characteristics of patients and *Candida auris* isolates, Germany, 2015–2017*

Patient no.	<i>C. auris</i> isolates		Patient details				Antifungal susceptibility, µg/mL†						Resistance mutations‡		
	Date of isolation	Isolate no.	Genetic clade	Isolation site	Age, y/sex	Previous hospitalization	FLU	ISA	ITR	POS	VOR	ANI	<i>ERG11</i> mutations	<i>FKS1</i> HS1	<i>FKS1</i> HS2
1	2015 Nov	NRZ 2015-214	South Asian	Blood culture	65/M	Oman	≥64	ND	0.05	0.03	1	0.25	Y132F	None	None
2	2015 Dec	NA§	NA§	CVC tip	50/F	None	≥64	0.03	0.05	0.06	1	0.125	Y132F	None	None
3	2017 Jun	NRZ 2017-394	South Asian	Catheter urine	67/F	Saudi Arabia	≥64	1	2	0.5	2	0.25	K143R	none	None
4	2017 Jul	NRZ 2017-288	South Asian	Catheter urine	48/F	Dubai	≥64	≤0.016	0.25	≤0.016	0.25	0.125	Y132F	None	None
5	2017 Aug	NRZ 2017-367	South Asian	Intraoperative tissue sample, pelvis	57/M	Russia	≥64	≤0.016	0.25	≤0.016	0.5	0.125	Y132F	None	None
6	2017 Nov	NRZ 2017-505	South Asian	Blood culture	15/M	Afghanistan	≥64	0.25	0.5	≤0.016	0.5	16	K143R	S639Y	None
7	2017 Dec	NRZ 2017-545	African	Urine	60/M	Great Britain, USA, Kenya	≥64	≤0.016	0.25	0.06	2	0.5	V124A F125L	None	None

*ANI, anidulafungin; CVC, central venous catheter; FLU, fluconazole; ISA, isavuconazole; ITR, itraconazole; NA, not available; ND, not determined; POS, posaconazole; VOR, voriconazole.

† Results of microdilution tests according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations (www.eucast.org).

‡ERG11 was completely sequenced, whereas for FKS1 only hotspot 1 and 2 were sequenced. If existing, only mutations in the protein sequence are shown.

§The isolate was reliably identified as *C. auris* using Bruker mass spectroscopy but was not stored for further analysis; thus, no information on clade is available. Susceptibility testing was performed using the Micronaut system (Merlin Diagnostika, <https://www.merlin-diagnostika.de>) but could not be confirmed using a reference methodology.